A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity

Journal of Cardiology

Volumn 71, Issue 5, 2018, Pages 471-476

  Sano, Motoaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular protection; Heart failure; Sodium glucose cotransporter 2 inhibitor; Sympathetic overactivity

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

DIABETIC NEPHROPATHY; HEART FAILURE; HUMAN; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; NONHUMAN; REVIEW; SYMPATHETIC TONE; ADRENERGIC SYSTEM; ANIMAL; BLOOD PRESSURE; COMPLICATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERTENSION; KIDNEY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GLUCOSE; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; KIDNEY; PROGNOSIS; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 85044521391     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2017.12.004     Document Type: Review

References (50)

1. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–665.
3. Lytvyn, Y., Bjornstad, P., Udell, J.A., Lovshin, J.A., Cherney, D.Z.I., Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136 (2017), 1643–1658.
4. Graham, L.N., Smith, P.A., Huggett, R.J., Stoker, J.B., Mackintosh, A.F., Mary, D.A., Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction. Circulation 109 (2004), 2285–2289.
5. Leimbach, W.N. Jr., Wallin, B.G., Victor, R.G., Aylward, P.E., Sundlöf, G., Mark, A.L., Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73 (1986), 913–919.
6. Grassi, G., Cattaneo, B.M., Seravalle, G., Lanfranchi, A., Mancia, G., Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31 (1998), 68–72.
7. Converse, R.L. Jr., Jacobsen, T.N., Toto, R.D., Jost, C.M., Cosentino, F., Fouad-Tarazi, F., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327 (1992), 1912–1918.
8. Huggett, R.J., Scott, E.M., Gilbey, S.G., Stoker, J.B., Mackintosh, A.F., Mary, D.A., Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108 (2003), 3097–3101.
9. Grassi, G., Dell'Oro, R., Quarti-Trevano, F., Scopelliti, F., Seravalle, G., Paleari, F., et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48 (2005), 1359–1365.
10. Narkiewicz, K., Somers, V.K., The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens 15 (1997), 1613–1619.
11. Barretto, A.C., Santos, A.C., Munhoz, R., Rondon, M.U., Franco, F.G., Trombetta, I.C., et al. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 135 (2009), 302–307.
12. Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F.A., Tripepi, G., et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105 (2002), 1354–1359.
13. Reuben, D.B., Talvi, S.L., Rowe, J.W., Seeman, T.E., High urinary catecholamine excretion predicts mortality and functional decline in high-functioning, community-dwelling older persons: MacArthur Studies of Successful Aging. J Gerontol A Biol Sci Med Sci 55 (2000), M618–M624.
14. Grassi, G., Role of the sympathetic nervous system in human hypertension. J Hypertens 16:12 Pt 2 (1998), 1979–1987.
15. Fisher, J.P., Young, C.N., Fadel, P.J., Central sympathetic overactivity: maladies and mechanisms. Auton Neurosci 148 (2009), 5–15.
16. Mangoni, A.A., Mircoli, L., Giannattasio, C., Mancia, G., Ferrari, A.U., Effect of sympathectomy on mechanical properties of common carotid and femoral arteries. Hypertension 30 (1997), 1085–1088.
17. Hijmering, M.L., Stroes, E.S., Olijhoek, J., Hutten, B.A., Blankestijn, P.J., Rabelink, T.J., Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 39 (2002), 683–688.
18. DiBona, G.F., Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 11 (2002), 197–200.
19. Rahman, A., Fujisawa, Y., Nakano, D., Hitomi, H., Nishiyama, A., Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clin Exp Pharmacol Physiol 44 (2017), 522–525.
20. Matthews, V.B., Elliot, R.H., Rudnicka, C., Hricova, J., Herat, L., Schlaich, M.P., Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens 35 (2017), 2059–2068.
21. Hillis, G.S., Hata, J., Woodward, M., Perkovic, V., Arima, H., Chow, C.K., et al. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc, 1, 2012, e002832.
22. Vazir, A., Claggett, B., Pitt, B., Anand, I., Sweitzer, N., Fang, J., et al. Prognostic importance of temporal changes in resting heart rate in heart failure and preserved ejection fraction: from the TOPCAT Study. JACC Heart Fail 5 (2017), 782–791.
23. Sano, M., Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors. J Clin Med Res 9 (2017), 457–460.
24. Sano, M., Chen, S., Imazeki, H., Ochiai, H., Seino, Y., Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Sub-analysis of placebo controlled, double-blind clinical trials. J Diabetes Investig, 2018 (in press).
25. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
26. Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
27. Asada, N., Takase, M., Nakamura, J., Oguchi, A., Asada, M., Suzuki, N., et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121 (2011), 3981–3990.
28. Takaori, K., Nakamura, J., Yamamoto, S., Nakata, H., Sato, Y., Takase, M., et al. Severity and frequency of proximal tubule injury determines renal prognosis. J Am Soc Nephrol 27 (2016), 2393–2406.
29. Bonventre, J.V., Can we target tubular damage to prevent renal function decline in diabetes?. Semin Nephrol 32 (2012), 452–462.
30. Körner, A., Eklöf, A.C., Celsi, G., Aperia, A., Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43 (1994), 629–633.
31. 2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309 (2015), F227–F234.
32. Gewin, L., Zent, R., Pozzi, A., Progression of chronic kidney disease: too much cellular talk causes damage. Kidney Int 91 (2017), 552–560.
33. Bosman, D.R., Winkler, A.S., Marsden, J.T., Macdougall, I.C., Watkins, P.J., Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24 (2001), 495–499.
34. Gilbert, R.E., SGLT2 inhibitors: β blockers for the kidney?. Lancet Diabetes Endocrinol, 4, 2016, 814.
35. Sano, M., Takei, M., Shiraishi, Y., Suzuki, Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8 (2016), 844–847.
36. Thorp, A.A., Schlaich, M.P., Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res, 2015, 2015, 341583.
37. Muntzel, M.S., Anderson, E.A., Johnson, A.K., Mark, A.L., Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens 17 (1995), 39–50.
38. Cassaglia, P.A., Hermes, S.M., Aicher, S.A., Brooks, V.L., Insulin acts in the arcuate nucleus to increase lumbar sympathetic nerve activity and baroreflex function in rats. J Physiol 589 (2011), 1643–1662.
39. Lembo, G., Napoli, R., Capaldo, B., Rendina, V., Iaccarino, G., Volpe, M., et al. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest 90 (1992), 24–29.
40. Mark, A.L., Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol 305 (2013), R566–R581.
41. Kaur, J., Young, B.E., Fadel, P.J., Sympathetic overactivity in chronic kidney disease: consequences and mechanisms. Int J Mol Sci, 18, 2017, E1682.
42. Campese, V.M., Kogosov, E., Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25 (1995), 878–882.
43. Ye, S., Zhong, H., Yanamadala, V., Campese, V.M., Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15 (2002), 717–724.
44. Katholi, R.E., Whitlow, P.L., Hageman, G.R., Woods, W.T., Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 2 (1984), 349–359.
45. Hausberg, M., Kosch, M., Harmelink, P., Barenbrock, M., Hohage, H., Kisters, K., et al. Sympathetic nerve activity in end-stage renal disease. Circulation 106 (2002), 1974–1979.
46. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
47. Heerspink, H.J., Johnsson, E., Gause-Nilsson, I., Cain, V.A., Sjöström, C.D., Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin–angiotensin blockers. Diabetes Obes Metab 18 (2016), 590–597.
48. Zhang, Y., Thai, K., Kepecs, D.M., Gilbert, R.E., Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLOS ONE, 11, 2016, e0144640.
49. Ansary, T.M., Fujisawa, Y., Rahman, A., Nakano, D., Hitomi, H., Kobara, H., et al. Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. Sci Rep, 7, 2017, 9555.
50. Polhemus, D.J., Trivedi, R.K., Gao, J., Li, Z., Scarborough, A.L., Goodchild, T.T., et al. Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney. J Am Coll Cardiol 70 (2017), 2139–2153.